In the present study, the percentage of cases with HER2 positivity was less than reported in other studies [4–8], and HER2 positivity was observed in 4.4% of primary gastric adenocarcinoma tumor tissue samples, 6.7% of CB-MEs, and 11% of both. This evidence concerns the gene ERBB2 and gastric adenocarcinoma.